Medesis Pharma

www.medesispharma.com

A RADICAL CHANGE IN THE WAY DRUGS ARE DELIVERED TO TARGETS Medesis Pharma has developed a revolutionary technology providing a paradigm shift in drug delivery methodology concentrating not just on improving a drugs absorption characteristics, but also by ensuring that a drug reaches its site of action in the most efficient way possible. TROJAN HORSE DELIVERY The human body uses a variety of physiological cellular delivery mechanisms to deliver molecules essential to the workings of every cell. The Aonys® drug delivery technology is able to use these natural mechanisms to circumvent the natural barriers which drugs must overcome to reach reach their sites of action. Research Medesis is undertaking an extensive research program applying the Aonys® technology to a variety of advanced therapeutics which up to now do not have suitable delivery solutions including: - Therapeutic peptides - Antisense oligonucleotides - Heavy metal chelating agents Development Clinical development programs are ongoing for two Aonys® formulated products for the following major indications: Metabolic anomalies linked to insulin resistance (pre-diabetes) Neurodegeneration in Huntington's disease

Read more

Reach decision makers at Medesis Pharma

Lusha Magic

Free credit every month!

A RADICAL CHANGE IN THE WAY DRUGS ARE DELIVERED TO TARGETS Medesis Pharma has developed a revolutionary technology providing a paradigm shift in drug delivery methodology concentrating not just on improving a drugs absorption characteristics, but also by ensuring that a drug reaches its site of action in the most efficient way possible. TROJAN HORSE DELIVERY The human body uses a variety of physiological cellular delivery mechanisms to deliver molecules essential to the workings of every cell. The Aonys® drug delivery technology is able to use these natural mechanisms to circumvent the natural barriers which drugs must overcome to reach reach their sites of action. Research Medesis is undertaking an extensive research program applying the Aonys® technology to a variety of advanced therapeutics which up to now do not have suitable delivery solutions including: - Therapeutic peptides - Antisense oligonucleotides - Heavy metal chelating agents Development Clinical development programs are ongoing for two Aonys® formulated products for the following major indications: Metabolic anomalies linked to insulin resistance (pre-diabetes) Neurodegeneration in Huntington's disease

Read more
icon

Country

icon

Employees

11-50

icon

Founded

2003

icon

Estimated Revenue

$1,000,000 to $5,000,000

icon

Social

  • icon

Employees statistics

View all employees

Potential Decision Makers

  • Chief Medical Officer ; Head of Research and Development

    Email ****** @****.com
    Phone (***) ****-****
  • General Secretary and Chief Financial Officer Group

    Email ****** @****.com
    Phone (***) ****-****
  • Administrative Manager

    Email ****** @****.com
    Phone (***) ****-****
  • Business Manager

    Email ****** @****.com
    Phone (***) ****-****

Reach decision makers at Medesis Pharma

Free credits every month!

My account

Sign up now to uncover all the contact details